Similar Outcomes and Prognosis between Osteoblastic Cell vs Standard Therapy in Patients with ONFH
Did Osteoblastic Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled TrialClin Orthop Relat Res. 2020 Jun;478(6):1307-1315.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Fifty-nine patients were randomized into receiving bone marrow aspirate concentrate (BMAC) or osteoblastic cell therapy for the treatment of nontraumatic osteonecrosis of the femoral head (ONFH). The primary outcomes included fracture progression as well as improvement in pain and functionality, which were all measured at 36 months. The secondary outcomes consisted of the proportion of hips conver...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE